NCBiotech News

STERIS plc, a global provider of products and services that support patient care with an emphasis on infection prevention, plans to invest $600 million to build a new facility in Sanford, creating 335 jobs in manufacturing, R&D, distribution and operations.

Durham-based SelSym Biotech, a biomedical company with roots at North Carolina State University, has secured an equity investor and partner to help it develop a novel therapy to control emergency bleeding.

Durham-based Humacyte, a regenerative medicine company, will soon begin a first-in-human clinical study of its bioengineered blood vessel in patients undergoing coronary artery bypass grafting (CABG).

The U.S. Food and Drug Administration accepted the company’s Investigational New Drug (IND) application for the Phase 2a study.

Durham-based Atsena Therapeutics, a clinical-stage gene therapy company focused on using genetic medicine to reverse or prevent blindness, has dosed the first patient in the Phase 3 pivotal cohort of the LIGHTHOUSE trial evaluating its ATSN-201 gene therapy for the treatment of X-linked retinoschisis (XLRS).

Kymanox has opened a new Formulation Lab to provide formulation development and analytical testing services for pharmaceutical and biotechnology companies moving programs from early research into clinical manufacturing.

Caidya, a global clinical research organization based in Raleigh, has announced it is combining with UK-based CRO Simbec-Orion to create a new platform to accelerate drug development programs and international scale-up. The combined company will operate under the Caidya name, the announcement said.

Durham-based 410 Medical, a medical device company developing new technologies for emergency and critical care, has raised $12 million from investors, including two North Carolina venture capital firms.

More than 100 Research Triangle Park officials and other supporters gathered on Thursday for a celebration at HUB RTP to mark the culmination of a multi-year planning process to chart a new long-range vision for the next half-century of innovation and economic growth in RTP. 

North Carolina State University and NCBiotech were proud to sponsor and welcome the Engineering Biology Research Consortium (EBRC) 10th Annual Meeting to Raleigh from June 1–3, 2026. The meeting brought together engineering and synthetic biology researchers and leaders from across the country and North Carolina to share the latest advances in agriculture and food innovation, biopharmaceutical development, AI-enabled biotechnology, biocomputing, genomic technologies, and more.

Clean Cells, a France-based provider of quality testing services for biopharmaceutical products, will acquire Stem Genomics, which provides next-generation quality controls for stem cell therapy. 

United Therapeutics, a biotechnology company with co-headquarters and manufacturing facilities in Research Triangle Park, has acquired a Boston-area biotech company to boost its efforts in regenerative medicine and organ transplantation.

Two life sciences organizations with operations in North Carolina are planning major expansions that will bring over 1,500 jobs and $1.8 billion in investment to the Greater Charlotte region.

The U.S. Food and Drug Administration selected three biopharma companies with manufacturing sites in North Carolina for a pilot program to help develop new domestic biomanufacturing capabilities.

Mary-Dell Chilton, Ph.D., an American pioneer in plant sciences known as the “Queen of the Agrobacterium,” died on June 24, 2026, in Carrboro, N.C. She was 87 years old.

Chilton’s research in the 1970s and 1980s continues to influence plant biotechnology through her groundbreaking discoveries of the interaction between plants and bacteria.

People living with type 1 diabetes walk a delicate line between taking enough insulin to control blood sugar and taking too much, which can cause dangerously low blood sugar, or hypoglycemia. An investigational liver-targeted insulin called HDV Lispro (HDV-LIS) could make day-to-day blood sugar management easier and safer.